Department of Medicine, School of Nursing, Qingdao University, Qingdao, China.
Department of Thoracic Surgery, Municipal Hospital, Qingdao, China.
J Clin Nurs. 2021 Dec;30(23-24):3493-3505. doi: 10.1111/jocn.15852. Epub 2021 May 16.
This study aimed to investigate whether fear of progression mediates the association between illness perception and quality of life among interstitial lung disease patients.
So far, the physiological treatment of interstitial lung disease is limited. In addition to immunosuppressants such as glucocorticoids, two anti-fibrosis drugs (pirfenidone and nintedanib) have shown moderately beneficial effects on slowing the progression of interstitial lung disease fibrosis. However, none of these drugs has shown reliable or strong beneficial effects on improving quality of life. Psychological care and mental health support strategies focusing on improving patients' quality of life are particularly important.
A cross-sectional study.
A convenience sample of patients suffering from interstitial lung disease were enrolled from August to December 2019. Data including sociodemographic and clinical characteristics, illness perception, fear of progression and quality of life were collected. The descriptive analysis and Pearson correlations were analysed by SPSS 26.0 (IBM Corp.). PROCESS v3.4 (by Andrew F. Hayes) macro was applied to analyse the mediating effects. We used the STROBE checklist to report the results.
Both illness perception and fear of progression were correlated with quality of life. Fear of progression mediated the association between illness perception and quality of life. The indirect effect was 0.121, and the proportion of intermediary effect in the main effect was 26.36%.
Interstitial lung disease patients experience relatively poor quality of life and fear of progression exerts a mediating role between illness perception and quality of life.
This study alerts medical staff to pay attention to negative illness perception and excessive fear, which is helpful to formulate effective interventions to manage interstitial lung disease patients' quality of life.
本研究旨在探讨进展恐惧是否在间质性肺病患者的疾病认知与生活质量之间起中介作用。
迄今为止，间质性肺病的生理治疗有限。除了免疫抑制剂如糖皮质激素外，两种抗纤维化药物（吡非尼酮和尼达尼布）已显示出对减缓间质性肺病纤维化进展具有中等有益作用。然而，这些药物均未显示出对改善生活质量有可靠或强烈的有益作用。关注改善患者生活质量的心理护理和心理健康支持策略尤为重要。
横断面研究。
2019 年 8 月至 12 月期间，便利抽样招募患有间质性肺病的患者。收集的数据包括社会人口统计学和临床特征、疾病认知、进展恐惧和生活质量。使用 SPSS 26.0（IBM 公司）进行描述性分析和 Pearson 相关性分析。采用 PROCESS v3.4（由 Andrew F. Hayes 开发）宏分析中介效应。我们使用 STROBE 清单报告结果。
疾病认知和进展恐惧均与生活质量相关。进展恐惧在疾病认知和生活质量之间起中介作用。间接效应为 0.121，中介效应在主效应中的比例为 26.36%。
间质性肺病患者的生活质量相对较差，进展恐惧在疾病认知和生活质量之间起中介作用。
本研究提醒医务人员注意消极的疾病认知和过度恐惧，这有助于制定有效的干预措施来管理间质性肺病患者的生活质量。
